IL-1β neutralizing human monoclonal antibodies
The present invention is directed to antigen binding proteins and in particular to IL-1β antigen binding proteins. The present invention further provides compositions comprising the antigen binding proteins, use of the antigen binding proteins and methods for production.
1. An isolated monoclonal antibody which specifically binds to IL-1, or an antigen binding fragment thereof, wherein said antibody or fragment thereof comprises:
(i) a light chain sequence comprising the amino acid sequence of SEQ ID NO: 17; and
(ii) a heavy chain sequence comprising the amino acid sequence of SEQ ID NO: 18 or SEQ ID NO: 2.
2. The isolated monoclonal antibody or fragment thereof of claim 1 , wherein the heavy chain sequence comprises the amino acid sequence of SEQ ID NO: 18.
3. The isolated monoclonal antibody or fragment thereof of claim 2 , wherein the heavy chain sequence comprises the amino acid sequence of SEQ ID NO: 14.
4. The isolated monoclonal antibody or fragment thereof of claim 1 , wherein the heavy chain sequence comprises the amino acid sequence of SEQ ID NO: 2.
5. The isolated monoclonal antibody or fragment thereof of claim 2 , which is fully human, and wherein the IL-1 is human.
6. The isolated monoclonal antibody or fragment thereof of claim 2 , which is the antibody of the subtype IgG1, IgG2, IgG3 or IgG4.
7. The isolated monoclonal antibody or fragment thereof of claim 6 , wherein the antibody is of the subtype IgG4.
8. A composition comprising the isolated antibody or fragment of claim 1 and a pharmaceutically acceptable carrier.
9. A composition comprising the isolated antibody or fragment of claim 2 and a pharmaceutically acceptable carrier.